ERBB2 and neoplasm: Multivariate analysis demonstrated that DeepTEPP category was the strongest independent prognostic factor after adjusting for tumor stage and adjuvant anti-HER2 treatment for either RFS (Moderate vs Low: hazard ratio [HR] 12.22, 95% CI 5.37–27.79, p < 0.0001; High vs Low: HR 28.04, 95% CI 12.87–61.07, p < 0.0001) or OS (Moderate vs Low: HR 8.29, 95% CI 2.72–25.24, p < 0.0001; High vs Low: HR 11.17, 95% CI 3.82–32.67, p < 0.0001).